GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™). (Source: GSK news)
Source: GSK news - June 25, 2014 Category: Pharmaceuticals Source Type: news

Myelodysplastic Syndrome - Mayo Clinic videos
What is Myelodysplastic Syndrome (MDS)? Raoul Tibes, M.D., Ph.D., hematologist at Mayo Clinic in Arizona, provides an overview of myelodysplastic syndrome (MDS) including the symptoms and diagnosis.Myelodysplastic Syndrome Treatment. Raoul Tibes, M.D., Ph.D. discusses various treatment options available for individuals diagnosed with myelodysplastic syndrome. Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook. (Source: Clinical Cases and Images)
Source: Clinical Cases and Images - June 5, 2014 Category: Journals (General) Tags: Hematology Mayo Clinic Oncology Source Type: news

Cyclacel Pharmaceuticals Provides Update on Its Clinical Development Plan of Sapacitabine for Myelodysplastic Syndromes (MDS)
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - June 1, 2014 Category: Pharmaceuticals Source Type: news

Clinical Advisory: Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN 0901)
Source: National Cancer Institute, National Heart, Lung, and Blood Institute - Related MedlinePlus Pages: Acute Myeloid Leukemia, Bone Marrow Transplantation, Myelodysplastic Syndromes (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 15, 2014 Category: Consumer Health News Source Type: news

Genetic tracking identifies cancer stem cells in human patients
The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer -- cancer stem cells. The international research team studied a group of patients with myelodysplastic syndromes -- a malignant blood condition which frequently develops into acute myeloid leukemia. The researchers say their findings offer conclusive evidence for the existence of cancer stem cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 15, 2014 Category: Science Source Type: news

Scientists Get Closer to the Stem Cells That May Drive Cancers
Researchers say a rare and unique tumor cell appears to help a form of blood cancer mutate and spread Source: HealthDay Related MedlinePlus Pages: Cancer, Myelodysplastic Syndromes, Stem Cells (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 15, 2014 Category: Consumer Health News Source Type: news

Genetic tracking identifies cancer stem cells in human patients
(University of Oxford) The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer -- cancer stem cells. The international research team, led by scientists at the University of Oxford and the Karolinska Institutet in Sweden, studied a group of patients with myelodysplastic syndromes -- a malignant blood condition which frequently develops into acute myeloid leukemia. The researchers say their findings offer conclusive evidence for the existence of cancer stem cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 15, 2014 Category: Cancer & Oncology Source Type: news

Kyowa HK Applies For Additional Indication Of NESP In Japan
Kyowa Hakko Kirin announced that is seeking approval from the Japanese Ministry of Health, Labor, and Welfare (MHLW) for additional indication of NESP Injection Plastic Syringe (NESP) for anemia with myelodysplastic syndrome. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 2, 2014 Category: Pharmaceuticals Source Type: news

Common blood cancer may be initiated by single mutation in bone cells
(Columbia University Medical Center) AML is a blood cancer, but for many patients the cancer may originate from an unusual source: a mutation in their bone cells. In a study published today in the online edition of Nature, researchers at Columbia University Medical Center found that a mutation in the bone cells called osteoblasts, which build new bone, causes AML in mice. The mutation was found in nearly 40 percent of patients with AML or myelodysplastic syndrome, a precursor condition, who were examined as part of the study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2014 Category: Cancer & Oncology Source Type: news

What scientific idea is ready for retirement?
Each year a forum for the world's most brilliant minds asks one question. This year's drew responses from such names as Richard Dawkins, Ian McEwan and Alan Alda. Here, edge.org founder John Brockman explains how the question came into being and we pick some of the best responsesEdge.org was launched in 1996 as the online version of "the Reality Club", an informal gathering of intellectuals who met from 1981 to 1996 in Chinese restaurants, artist lofts, investment banking firms, ballrooms, museums, living rooms and elsewhere. Though the venue is now in cyberspace, the spirit of the Reality Club lives on in the li...
Source: Guardian Unlimited Science - January 12, 2014 Category: Science Authors: The Observer Tags: Astronomy Biology Mathematics Technology Physics Features Internet Animal behaviour The Observer Science Source Type: news

Mechanism discovered that controls the development of myelodysplastic syndromes
Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases.MDS primarily affects older individuals, with approximately 12,000 new cases diagnosed each year. In MDS, a person's blood is not able to make one or more types of healthy blood cells - red blood cells, white blood cells or platelets. Instead, the patient has a high number of immature stem cells that do not develop properly. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 24, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Moffitt researchers discover mechanism controlling the development of myelodysplastic
(H. Lee Moffitt Cancer Center & Research Institute) Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes, a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2013 Category: Global & Universal Source Type: news

Sunesis Pharma starts Phase I/II myelodysplastic syndrome study
US-based Sunesis Pharmaceuticals has started an investigator-sponsored Phase I/II trial of vosaroxin in combination with azacitidine for the treatment of patients with myelodysplastic syndrome (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - December 12, 2013 Category: Pharmaceuticals Source Type: news

Access to transplants for MDS should not be limited by age
Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology."This is good evidence that age alone should not limit who should get a transplant for MDS," said Gregory Abel, MD, MPH, a medical oncologist at Dana-Farber. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 10, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Age shouldn't limit access to transplants for MDS, study suggests
(Dana-Farber Cancer Institute) Patients with myelodysplastic syndromes who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2013 Category: Global & Universal Source Type: news

Chai Receives 2013 V Foundation MDS Grant
Li Chai, MD, associate medical director of Adult Transfusion Medicine in the Department of Pathology, was recently honored with the 2013 V Foundation MDS Grant for her research in targeting leukemic stem cell factors in myelodysplastic syndromes. (Source: BWH News)
Source: BWH News - November 21, 2013 Category: Hospital Management Source Type: news

Cornerstone pharmaceuticals receives FDA orphan drug designation of CPI-613 for treatment of myelodysplastic syndrome
Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613, the Company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, for the treatment of myelodysplastic syndrome (MDS). MDS is a form of cancer that occurs when the blood-forming cells in the bone marrow are damaged, which leads to low numbers of one or more type of blood cells... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 7, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Scientists erase brain tumor cells in mice
Scientists have discovered that a repurposed drug approved by the US Food and Drug Administration (FDA) is capable of erasing brain tumor cells in mice. This is according to a study published in the journal Oncotarget. Researchers from the Johns Hopkins University School of Medicine used a drug called 5-azacytidine - used to treat a pre-leukemia condition called myelodysplastic syndrome - to target a mutation in a gene previously identified in human brain tumors (gliomas) called isocitrate dehydrogenase 1 (IDH1)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Recognizing Familial Myeloid Leukemia in AdultsRecognizing Familial Myeloid Leukemia in Adults
Familial cases of adult myelodysplastic syndrome and acute myeloid leukemia are considered rare, but are likely to be more common than currently appreciated. Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Dendritic Cells in Myelodysplastic SyndromesDendritic Cells in Myelodysplastic Syndromes
Dendritic cells are important regulators of immunity, but their role in myelodysplastic syndrome is unclear. Get the inside story. Immunotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2013 Category: Consumer Health News Tags: Allergy & Clinical Immunology Journal Article Source Type: news

Targeting Errant Immune System Enzyme Kills Myelodysplastic Cells
Scientists have successfully targeted a malfunctioning immune system enzyme to kill diseased cells from patients with myelodysplastic syndrome (MDS) - a blood disorder and precursor to leukemia. Reporting their results July 8 in Cancer Cell, researchers say their successful laboratory tests in human MDS cells and mouse models of MDS provide a molecular target for designing new drugs to battle a syndrome with few effective treatments... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 8, 2013 Category: Consumer Health News Tags: Immune System / Vaccines Source Type: news

Some Older Patients With Myelodysplastic Syndromes Benefit From Stem Cell Transplants
A new study by an international team led by Dana-Farber Cancer Institute scientists provides the first statistically-based guidelines for determining whether a stem cell transplant is appropriate for older patients with myelodysplastic syndromes (MDS) - the most common blood disorders in people over 60 years of age, and frequently a precursor for leukemia... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 25, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Stem Cell Therapy Best in Higher Risk MDS (CME/CE)
(MedPage Today) -- Reduced-intensity stem cell transplantation is the best treatment option for many patients in their 60s with intermediate-to-high-risk myelodysplastic syndrome (MDS), researchers found. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 25, 2013 Category: Hematology Source Type: news

Revlimid® indicated as a treatment for patients with rare form of blood disease
Celgene International Sàrl (NASDAQ: CELG) has been notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID®. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 19, 2013 Category: Drugs & Pharmacology Source Type: news

Safety and Efficacy of Deferasirox in Myelodysplastic SyndromeSafety and Efficacy of Deferasirox in Myelodysplastic Syndrome
Pumping too much iron? Will deferasirox help or harm your patients with MDS? Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 27, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Onconova completes enrolment in Phase III study of rigosertib
Clinical-stage biopharmaceutical company Onconova Therapeutics has completed enrolment in its ONTIME pivotal Phase III study of rigosertib in patients with high-risk myelodysplastic syndromes. (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2013 Category: Pharmaceuticals Source Type: news

Secondary Cancer Risk Found With Multiple Myeloma Maintenance Therapies
Multiple myeloma patients are at increased risk of developing myelodysplastic syndrome or acute leukemia after maintenance lenalidomide or thalidomide treatment, according to a new study. (Source: Cancer Network)
Source: Cancer Network - May 2, 2013 Category: Cancer & Oncology Source Type: news

Promising Phase I Clinical Trial Of Rogosertib Leads To Multi-Institutional Phase II Trial
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Researchers Study Use Of Dasatinib For Patients With High-Risk Myelodysplastic Syndromes
Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib, the study shows. Results of this study appeared in the March issue of Leukemia Research... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Moffitt Cancer Center researchers study use of dasatinib for patients with high-risk MDS
(H. Lee Moffitt Cancer Center & Research Institute) Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2013 Category: Global & Universal Source Type: news

Robin Roberts' return to work spotlights resuming a career after cancer
Six months after she went on leave to treat her myelodysplastic syndromes, Good Morning America anchor Robin Roberts returns (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - February 20, 2013 Category: Consumer Health News Source Type: news

The Use of Cytogenetic Microarrays in Myelodysplastic Syndrome Characterization
Various microarray platforms, including BAC, oligonucleotide, and SNP arrays, have been shown to ­provide clinically useful diagnostic and prognostic information for patients with myelodysplastic syndromes (MDS). Clinically useful arrays are designed with specific purposes in mind and with attention to genomic content and probe density. All array types have been shown to detect genomic copy gains and losses, with SNP arrays having the added advantage of detecting copy neutral loss of heterozygosity (CNLOH). The finding of CNLOH has led to the identification of certain disease genes implicated in the initiation or progr...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news

Apogenix Receives FDA Orphan Drug Designation For Apocept(TM) To Treat Myelodysplastic Syndromes And Initiates Clinical Phase I Study
Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that its lead product, Apocept(TM) (APG101), has been granted orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of Myelodysplastic syndromes (MDS). MDS are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias, especially anemia... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 12, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Horizon Scanning: FDA grants orphan drug status for ApoceptT to treat myelodysplastic syndrome
Source: BioSpace Area: News Apogenix GMbH, a clinical stage biopharmaceutical company, has announced that the FDA has granted orphan drug designation for ApoceptT for the treatment of myelodysplastic syndrome (MDS).   A clinical phase I open-label trial is being initiated with ApoceptT in patients with MDS. Recruitment for the study began in January 2013.   ApoceptT binds to the CD95 ligand (CD95L) and blocks the activation of the CD95 receptor. Excessive stimulation of the CD95 receptor on hematopoietic cells present in the bone marrow of MDS patients inhibits erythropoiesis. As a result, transfusion-d...
Source: NeLM - News - February 8, 2013 Category: Drugs & Pharmacology Source Type: news

Acceleron commences Phase II myelodysplastic syndromes study of ACE-536
Biopharmaceutical company Acceleron Pharma has commenced a Phase II study to evaluate the safety, tolerability and efficacy of ACE-536 in patients with low-risk or intermediate-1 risk myelodysplastic syndromes (MDS). (Source: Drug Development Technology)
Source: Drug Development Technology - January 30, 2013 Category: Pharmaceuticals Source Type: news

Alkylating agents for Hodgkin's lymphoma tied to secondary leukemia
NEW YORK (Reuters Health) - Reducing exposure to alkylating agents in Hodgkin's lymphoma is key to reducing the risk of therapy-related acute myeloid leukemia or myelodysplastic syndrome (t-AML/MDS), reports a group from Stanford University, California. (Source: Modern Medicine)
Source: Modern Medicine - January 10, 2013 Category: Journals (General) Source Type: news

Robin Roberts Ready To Return
GMA news host Robin Roberts is almost ready to go back on the air, after having a bone marrow transplant (BMT). Roberts developed myelodysplastic syndrome (MDS) after having chemotherapy for ...Read Full Post (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - January 7, 2013 Category: Cancer & Oncology Source Type: news

New Clinical Advisory: Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN 0901)
The National Institutes of Health's National Heart, Lung, and Blood Institute has suspended enrollment for the clinical study BMT CTN 0901 conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) after preliminary data appeared to show benefit for one approach to the intensity of conditioning for allogeneic stem cell transplantations in patients eligible for the study. (Source: PubMed New and Noteworthy)
Source: PubMed New and Noteworthy - June 18, 2012 Category: Databases & Libraries Source Type: news

New Clinical Advisory: Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN 0901)
​The National Institutes of Health’s National Heart, Lung, and Blood Institute has suspended enrollment for the clinical study BMT CTN 0901 conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) after preliminary data appeared to show benefit for one approach to the intensity of conditioning for allogeneic stem cell transplantations in patients eligible for the study. (Source: PubMed New and Noteworthy)
Source: PubMed New and Noteworthy - June 18, 2012 Category: Databases & Libraries Source Type: news

Discovery of Genetic Mutations Better Diagnose Myelodysplastic Syndromes
Researchers at BWH have developed a means of improving prognosis methods for patients with myelodysplastic syndromes. (Source: BWH News)
Source: BWH News - June 30, 2011 Category: Hospital Management Source Type: news

NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
FORT WASHINGTON, Pa., December 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the use of erythropoietin-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa. ESAs are no longer recommended for the treatment of cancer-related anemia associated with solid tumors or hematologic malignancies other than myelodysplastic syndromes (MDS). ESA therapy is an option for patient... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - December 20, 2007 Category: Cancer & Oncology Source Type: news

NCCN Updates Myelodysplastic Syndromes (MDS) Guidelines
JENKINTOWN, Pa., February 26, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard of care in oncology in the United States in both the community and the academic practice settings. These guidelines are updated continually and are based upon evaluation of scientific data integrated with expert judgment. One o... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 26, 2007 Category: Cancer & Oncology Source Type: news

NCCN Announces Important Updates to Myelodysplastic Syndromes Guidelines
JENKINTOWN, Pa., February 23, 2006 — The National Comprehensive Cancer Network (NCCN) announces updates to the NCCN Myelodysplastic Syndromes (MDS) Guidelines. The NCCN Clinical Practice Guidelines in Oncology are widely recognized and applied as the standard for clinical policy in oncology in both the community practice setting and in academic cancer centers. These guidelines are used extensively by managed care companies and by Medicare as the basis for coverage policies. These guidelines are ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 23, 2006 Category: Cancer & Oncology Source Type: news